GlassScriptPhysician profile
Kaye Toohill
NPI 1316905805
$1,840.92
in general payments reported to CMS, 2019-2025
18 companies · $404 in 2025
The $404 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $82.26 · 2022: $159 · 2023: $420 · 2024: $559 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $423.20 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Supernus Pharmaceuticals, INC. | $239.68 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $179.74 | 2020-2024 | Jornay Pm |
| Corium, LLC | $176.75 | 2023-2025 | Azstarys |
| Sanofi Pasteur INC. | $174.49 | 2019-2025 | |
| Glaxosmithkline, LLC. | $119.78 | 2023-2025 | Bexsero, Penmenvy, Rotarix |
| Pfizer INC. | $101.82 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $78.65 | 2025 | Neffy |
| Kaleo, INC. | $56.99 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $53.66 | 2025 | |
| Seqirus USA INC | $50.20 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Genentech USA, INC. | $48.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $44.47 | 2023-2024 | Flumist Quadrivalent |
| Acadia Pharmaceuticals INC | $21.34 | 2024 | Daybue |
| Genzyme Corporation | $20.91 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $19.91 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $19.05 | 2024 | Voxzogo 1.2mg |
| Arbor Pharmaceuticals, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaye Toohill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.